A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy

[1]  P. Macdonald,et al.  National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. , 2018, Heart, lung & circulation.

[2]  S. Heymans,et al.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology , 2018, Cardiovascular research.

[3]  J. Seidman,et al.  Whole-Genome Sequencing as a First-Line Genetic Test in Familial Dilated Cardiomyopathy , 2018, Genetics in Medicine.

[4]  Marcel E Dinger,et al.  Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[5]  D. Judge,et al.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[6]  Melbourne Genomics Health Alliance,et al.  Meeting the challenges of implementing rapid genomic testing in acute pediatric care , 2018, Genetics in Medicine.

[7]  Marco Merlo,et al.  Insights into mildly dilated cardiomyopathy: temporal evolution and long‐term prognosis , 2017, European journal of heart failure.

[8]  F. Rutten,et al.  Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review , 2016, European journal of heart failure.

[9]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[10]  R. Hershberger,et al.  The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. , 2015, The Canadian journal of cardiology.

[11]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[12]  A. Anastasakis,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[13]  Karen S. Frese,et al.  Atlas of the clinical genetics of human dilated cardiomyopathy. , 2014, European heart journal.

[14]  Sivakumar Gowrisankar,et al.  The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing , 2014, Genetics in Medicine.

[15]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[16]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[17]  Y. Pinto,et al.  Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience , 2013, European journal of heart failure.

[18]  S. Ware,et al.  Uptake of Cardiac Screening and Genetic Testing Among Hypertrophic and Dilated Cardiomyopathy Families , 2013, Journal of Genetic Counseling.

[19]  R. Norman,et al.  Australian health‐related quality of life population norms derived from the SF‐6D , 2013, Australian and New Zealand journal of public health.

[20]  Nicole M. Johnson,et al.  Genetic testing for dilated cardiomyopathy in clinical practice. , 2012, Journal of cardiac failure.

[21]  P. Scuffham,et al.  A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy , 2011, Heart.

[22]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[23]  H. Watkins,et al.  DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. , 2010, European heart journal.

[24]  G. Bonsel,et al.  Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy , 2008, European Journal of Human Genetics.

[25]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[26]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[27]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[28]  P. Elliott,et al.  Echocardiographic Evaluation in Asymptomatic Relatives of Patients with Dilated Cardiomyopathy Reveals Preclinical Disease , 2005, Annals of Internal Medicine.

[29]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[30]  H. Katus,et al.  Prognostic value of serial cardiac assessment and familial screening in patients with dilated cardiomyopathy , 2003, European journal of heart failure.

[31]  National Institute for Health and Care Excellence (NICE) , 2019, The Grants Register 2020.

[32]  A. Torbicki,et al.  The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) , 2014 .

[33]  P. Scuffham,et al.  Health status of cardiac genetic disease patients and their at-risk relatives. , 2013, International journal of cardiology.

[34]  A. Harris,et al.  Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.

[35]  D. Fatkin.  Guidelines for the diagnosis and management of familial dilated cardiomyopathy. , 2007, Heart, lung & circulation.